Evidence map›Paper›PMID 25339804›Full record

ReviewWorld journal of gastroenterology2014

Immunopathogenesis of chronic hepatitis B.

Irina P Balmasova, Nikolay D Yushchuk, Ospan A Mynbaev, Nageswara R Alla, Elena S Malova, Zhongjie Shi, Chang-Lu Gao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Increased CCR7Canadian journal of gastroenterology & hepatology · 2018
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Irina P BalmasovaIrina P Balmasova, Nikolay D Yushchuk, Laboratory of Pathogenesis and Treatment Methods in Infection Diseases, Moscow State University of Medicine and Dentistry, Moscow 127374, Russia.
Nikolay D YushchukIrina P Balmasova, Nikolay D Yushchuk, Laboratory of Pathogenesis and Treatment Methods in Infection Diseases, Moscow State University of Medicine and Dentistry, Moscow 127374, Russia.
Ospan A MynbaevIrina P Balmasova, Nikolay D Yushchuk, Laboratory of Pathogenesis and Treatment Methods in Infection Diseases, Moscow State University of Medicine and Dentistry, Moscow 127374, Russia.
Nageswara R AllaIrina P Balmasova, Nikolay D Yushchuk, Laboratory of Pathogenesis and Treatment Methods in Infection Diseases, Moscow State University of Medicine and Dentistry, Moscow 127374, Russia.
Elena S MalovaIrina P Balmasova, Nikolay D Yushchuk, Laboratory of Pathogenesis and Treatment Methods in Infection Diseases, Moscow State University of Medicine and Dentistry, Moscow 127374, Russia.
Zhongjie ShiIrina P Balmasova, Nikolay D Yushchuk, Laboratory of Pathogenesis and Treatment Methods in Infection Diseases, Moscow State University of Medicine and Dentistry, Moscow 127374, Russia.
Chang-Lu GaoIrina P Balmasova, Nikolay D Yushchuk, Laboratory of Pathogenesis and Treatment Methods in Infection Diseases, Moscow State University of Medicine and Dentistry, Moscow 127374, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hepatitis B (CHB) is a widespread infectious disease with unfavorable outcomes and life-threatening consequences for patients, in spite of modern vaccination and antiviral treatment modalities. Cutting-edge experimental approaches have demonstrated key pathways that involve cross-talk between viral particles and host immune cells. All events, including penetration of hepatitis B virus (HBV) particles into host cells, establishing persistence, and chronization of CHB infection, and possibility of complete elimination of HBV particles are controlled by the immune system. Researchers have paid special attention to the replication capacity of HBV in host cells, which is associated with cellular changes that reflect presentation of viral antigens and variability of HBV antigen features. In addition, specific HBV proteins have an immune-modulating ability to initiate molecular mechanisms that "avoid" control by the immune system. The relationship between immunological shifts and chronic infection stages has been intensively studied since it was recognized that the immune system is a direct participant in the recurrent (cyclic) nature of CHB. Understanding the wide diversity of molecular pathways and the crosstalk between innate and adaptive immune system components will provide fresh insight into CHB immune pathogenesis and the possibilities of developing new treatment strategies for this disease.

Indexed as

Adaptive ImmunityAnimalsAntiviral AgentsDrug DesignHepatitis B, ChronicHepatitis B Core AntigensHepatitis B e AntigensHepatitis B virusHost-Pathogen InteractionsHumansImmunity, InnateVirus ReplicationAntiviral AgentsHepatitis B Core AntigensHepatitis B e AntigensAntiviral drugsChronic hepatitis BHepatocellular carcinomaImmune responseImmunopathogenesis

Identifiers

PMID25339804
PMCPMC4202346

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.